Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

mgi pharma - palonosetron hydrochloride (unii: 23310d4i19) (palonosetron - unii:5d06587d6r) - injection - 0.25 mg in 5 ml - aloxi is indicated for: • moderately emetogenic cancer chemotherapy -- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses • highly emetogenic cancer chemotherapy -- prevention of acute nausea and vomiting associated with initial and repeat courses aloxi is indicated for: • prevention of postoperative nausea and vomiting (ponv) for up to 24 hours following surgery. efficacy beyond 24 hours has not been demonstrated. as with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and vomiting must be avoided during the postoperative period, aloxi is recommended even where the incidence of postoperative nausea and/or vomiting is low. aloxi is contraindicated in patients known to have hypersensitivity to the drug or any of its components. [see adverse reactions (6.2 )] teratogenic effects: category b teratology studies have been perfo

Σιγκαπούρη - Αγγλικά - HSA (Health Sciences Authority)

juniper healthcare pte ltd - palonosetron hydrochloride 0.28 mg/5ml eqv palonosetron - injection, solution - 50mcg/ml - palonosetron hydrochloride 0.28 mg/5ml eqv palonosetron 50mcg/ml

Σιγκαπούρη - Αγγλικά - HSA (Health Sciences Authority)

juniper biologics pte ltd - palonosetron hcl 0.56mg eqv to palonosetron - capsule, liquid filled - palonosetron hcl 0.56mg eqv to palonosetron 0.50mg

Ισραήλ - Αγγλικά - Ministry of Health

rafa laboratories ltd - netupitant; palonosetron as hydrochloride - capsules - netupitant 300 mg; palonosetron as hydrochloride 0.50 mg - palonosetron, combinations - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

Μαλαισία - Αγγλικά - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

juniper biologics sdn. bhd. - palonosetron hydrochloride; netupitant -

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

helsinn birex pharmaceuticals ltd. - palonosetron hydrochloride - vomiting; cancer - antiemetics and antinauseants, , serotonin (5ht3) antagonists - aloxi is indicated in adults for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.aloxi is indicated in paediatric patients 1 month of age and older for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Μαλαισία - Αγγλικά - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

accord healthcare sdn.bhd. - palonosetron (as hydrochloride) -

Νότια Αφρική - Αγγλικά - South African Health Products Regulatory Authority (SAHPRA)

teva pharmaceuticals (pty) ltd - solution for injection - not indicated - each vial of 5 ml of solution contains palonosetron (as hydrochloride) 0,25 mg

Ισραήλ - Αγγλικά - Ministry of Health

rafa laboratories ltd - palonosetron as hydrochloride - solution for injection - palonosetron as hydrochloride 0.25 mg/vial - palonosetron - palonosetron - paloxi is indicated in adults and in paediatric patients 1 month of age and older for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

Ισραήλ - Αγγλικά - Ministry of Health

rafa laboratories ltd - palonosetron as hydrochloride - solution for injection - palonosetron as hydrochloride 0.25 mg/vial - palonosetron - palonosetron - paloxi is indicated in adults and in paediatric patients 1 month of age and older for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.